EHNA

Overview

EHNA is a potent and selective dual inhibitor of cyclic nucleotide phosphodiesterase 2 ( PDE2 ) ( IC 50 =4 μM) and adenosine deaminase (ADA) . EHNA exerts a concentration inhibition of the cGMP-stimulated PDE II (cGs-PDE)( IC 50 :0.8 μM (human), 2 μM (porcine myocardium)), but has smaller inhibitory effect on the unstimulated PDE2 activity. EHNA play roles in mediating diverse pharmacological responses, including antiviral , antitumour and antiarrhythmic effects.

Application

Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Neurological Disease | Products > Research Areas > Infection | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Adenosine Deaminase | Products > Signaling Pathways > Phosphodiesterase (PDE) | Products > Signaling Pathways > Influenza Virus

Product Information

• Catalog No.: HY-103160B
• CAS No.: 51350-19-7
• Molecular Formula: C14H23N5O
• Molecular Weight: 277.37
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source